based on patient preferences, life expectancy, health status, and prior screening history; and (3) clinicians discourage individuals older than 85 years from continuing CRC screening. Thus, we conclude that our findings provide novel empirical evidence supporting both the ACS3 and US Preventive Services Task Force5 guidelines.

Wenjie Ma, ScD
Mingyang Song, MD, ScD
Andrew T. Chan, MD, MPH

Author Affiliations: Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Harvard Medical School, Boston.

Corresponding Author: Andrew T. Chan, MD, MPH, Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114 (achan@mgh.harvard.edu).


Conflict of Interest Disclosures: Dr Chan reported personal fees from Pfizer, Bayer Pharma AG, and Boehringer Ingelheim outside the submitted work. No other disclosures were reported.


CORRECTION

Error in the Abstract: In the Original Investigation titled, “Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial,” which published online December 30, 2020, and in print in the February 2021 issue, the trial registration information was incorrect. The correct ClinicalTrials.gov identifier is NCT04439123. This article was corrected online.


Omitted Conflict of Interest Statement: In the Viewpoint “Is It Time to Reevaluate Radiotherapy Omission in Older Patients With Favorable Early-Stage Breast Cancer?”1 and Letter in Reply “Omission of Radiotherapy in Older Adults With Early-Stage Breast Cancer—Reply,”2 published in JAMA Oncology, author Arpit M. Chhabra, MD, omitted the following from his conflict of interest disclosures: “Dr Chhabra reports receiving consulting fees from SDX Respiratory Gating System and a speaking fee from icotec Medical Inc (both of which provide products or equipment for use in radiotherapy) and a stipend for reviewing charts for the American College of Radiation Oncology Accreditation Program.” The articles have been corrected to add these disclosures.


Error in Author Affiliations and Supplement: The Original Investigation titled “Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial,” published online October 7, 2021, was corrected to fix the attribution of the affiliation the Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milano, Italy, to author Serena Di Cosimo; it had been incorrectly attributed to author Joseph Gilgorov. In addition, the Supplement was corrected to fix the layout of eFigures 1, 2, and 3.